Quest Diagnostics Inc vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Vanguard Total Stock Market Index Fund ETF trades at $381.94 (market cap $2.30T). The key difference: Vanguard Total Stock Market Index Fund ETF is far larger — about 90.3× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Vanguard Total Stock Market Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Vanguard Total Stock Market Index Fund ETF for 131 Days on average.
| DGX | VTI | |
|---|---|---|
Market Cap | $25.48B | $2.30T |
Volume | 941,866 | 2,982,924 |
Sector | Health | — |
52-Week High | $247.45 | $384.30 |
52-Week Low | $173.49 | $311.68 |
Typical Hold Time | 56 Days | 131 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
VTI trades at $381.94, up 0.24% on the day, with a bullish technical signal from moving averages. The ETF offers broad exposure to the U.S. stock market, though key valuation ratios like P/E and P/S are not provided in the current data. Recent news highlights its role in diversified portfolios and long-term growth potential, with a dividend scheduled for late September 2026.
The outlook for VTI is supported by its low-cost, diversified structure, appealing to long-term investors. Risks include market concentration in top holdings and overall equity market volatility. Analyst sentiment is generally positive, emphasizing its suitability for retirement and growth strategies amid current economic conditions.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →